A Case Report of Lenacapavir Use in a Patient with Multidrug-Resistant HIV: The First Experience in Asia

Lenacapavir is a novel, first-in-class, capsid inhibitor, which has been approved as an adjunctive therapy for multidrug-resistant human immunodeficiency virus (HIV)-1 virus in combination with optimized background regimen (OBR). Lenacapavir has demonstrated a significant decrease in viral load and...

Full description

Saved in:
Bibliographic Details
Published in:Yonsei medical journal 2024, 65(10), , pp.619-622
Main Authors: Lee, Yongseop, Lee, Ki Hyun, Lee, Jung Ah, Ahn, Sang Min, Han, Min, Choi, Jun Yong
Format: Article
Language:English
Subjects:
Adult
Anti-HIV Agents - therapeutic use
Asia
Case Report
CD4 Lymphocyte Count
Drug Resistance, Multiple, Viral
HIV Infections - drug therapy
HIV Infections - virology
HIV-1 - drug effects
Humans
Male
Viral Load - drug effects
의학일반
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lenacapavir is a novel, first-in-class, capsid inhibitor, which has been approved as an adjunctive therapy for multidrug-resistant human immunodeficiency virus (HIV)-1 virus in combination with optimized background regimen (OBR). Lenacapavir has demonstrated a significant decrease in viral load and high rate of virologic suppression in patients with multidrug-resistant HIV-1 infection with limited treatment options. Here, we report a case of 43-year-old male who was diagnosed with HIV-1 infection in 2005 but failed to achieve viral suppression due to multiclass resistance. After lenacapavir use with OBR, viral suppression was achieved, and recovery of CD4 T-cell count was observed for 8 months. This case report shows the first lenacapavir experience in Asia in a heavily treatment-experienced HIV patient with limited treatment options.
ISSN:0513-5796
1976-2437
1976-2437
DOI:10.3349/ymj.2023.0540